Multiple myeloma (MM) is one of the most common hematological neoplasms. It constitutes about 1% of human cancers and 2% of all cancer deaths. Polycylic aromatic hydrocarbons such as 2,3,7,8- tetrachlorodibenzo--dioxin (TCDD) have been closely correlated to MM by epidemiologic studies, yet the biologic mechanisms of a causal relationship between TCDD exposure and MM have not been well understood. One of the unique features of MM compared to other cancers is the extremely low genetic mutation rate of the tumor protein p53 (TP53) gene. TP53 encodes the p53 tumor suppressor, guardian of the human genome. Genomic instability (chromosome translocation, aneuploidy, and gene mutation) is widely observed in MM and reveals that the function of p53 as the guardian of the human genome is compromised in MM. We explored the molecular mechanisms of p53 inactivation in MM by a new class of noncoding small RNAs, microRNAs (miRNAs) as recent reports have demonstrated that some miRNAs such as miR-34 are important players in the p53 tumor suppressor network. We hypothesize that miRNAs negatively regulate the human TP53 gene in MM. We propose three aims for this project: first, we will identify miRNAs that target the human TP53 gene by a combination of mutagenesis, reporter expression, and immunoblotting analyses;second, we will assess the pathological significance of miRNA:TP53 interactions in MM cell lines and primary MM cells by expression profiling and miRNA inhibition assays;third, we will determine whether dioxin modulates p53 signaling by upregulating miRNA expression. A novel p53 inactivation mechanism by an miRNA, that is upregulated by dioxin, will lead to unique targets for diagnostic markers and therapeutic interventions in MM patients as well as provide a better understanding of the biological interactions between dioxin exposure and MM tumorigenesis.

Public Health Relevance

TP53 gene alterations are rare and late events in multiple myeloma (MM), the second most common hematological malignancy constituting about 1% of all human cancers. It is critical to explore whether there are unique mechanisms that inactivate wild-type TP53 function as an early and original molecular event in MM development. The proposed research plan is to test the hypothesis that TP53 is negatively regulated by microRNAs (miRNAs), a class of newly discovered small noncoding RNAs, to define whether miRNA dysregulation contributes to tumorigenesis prior to TP53 gene alterations, and to determine whether dioxin modulates p53 signaling through upregulating miRNA expression.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-DKUS-C (90))
Program Officer
Johnson, Ronald L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Louisville
Schools of Medicine
United States
Zip Code
Gordon, Michael W; Yan, Fang; Zhong, Xiaoming et al. (2015) Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Mol Carcinog 54:1060-9
Wang, Shi; Medeiros, L Jeffrey; Xu-Monette, Zijun Y et al. (2014) Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol 18:203-9
Ok, Chi Young; Chen, Jiayu; Xu-Monette, Zijun Y et al. (2014) Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res 20:5113-23
Deng, Qipan; Becker, Lindsey; Ma, Xiaodong et al. (2014) The dichotomy of p53 regulation by noncoding RNAs. J Mol Cell Biol 6:198-205
Ok, Chi Young; Li, Ling; Xu-Monette, Zijun Y et al. (2014) Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20:2338-49
Ok, Chi Young; Xu-Monette, Zijun Y; Tzankov, Alexandar et al. (2014) Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer 120:1818-29
Visco, Carlo; Tzankov, Alexander; Xu-Monette, Zijun Y et al. (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98:255-63
Hu, Shimin; Xu-Monette, Zijun Y; Balasubramanyam, Aarthi et al. (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121:2715-24
Hoeller, Sylvia; Zhou, Yi; Kanagal-Shamanna, Rashmi et al. (2013) Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 44:110-21
Hu, Shimin; Xu-Monette, Zijun Y; Tzankov, Alexander et al. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021-31; quiz 4250

Showing the most recent 10 out of 19 publications